WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Audit report finds German green transition lags behind targetsIsrael’s chief says it will respond to Iran’s missile strikeChina: An active participant in promoting human rights within the framework of global governanceTourism market expecting holiday boomNew rules for Pregnant Workers Fairness Act include divisive accommodations for abortionHilarious moment Moto3 rider accidentally jumps onto a rival's bike midAmanda Holden puts on a VERY leggy display in a grey miniWhat do women want? Mandarin pop song lyrics reveal a shift, study shows — Radio Free AsiaThailand to charge entry fees for international traveler from JuneDisplaced Lebanese long for home as Hezbollah
2.0318s , 6498.953125 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Worldly Wisdom news portal